Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs

Gynecologic Oncology

Volumn 94, Issue 1, 2004, Pages 107-114

  Tomek, Sandra ^a   Horak, Peter ^a   Pribill, Ingrid ^a   Haller, Griet ^a   Rössler, Max ^a   Zielinski, Christoph C ^a   Pils, Dietmar ^a   Krainer, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Chemotherapy; DISC; DR4, DR5, DcR1, DcR2; Fas ligand; FasL; OPG; osteoprotegerin; Ovarian cancer; receptors for TRAIL; TNF ; TNF related apoptosis inducing ligand; TRAIL; TRAIL resistance; tumor necrosis factor alpha

Indexed keywords

CARBOPLATIN; CYTOTOXIC AGENT; DEATH RECEPTOR 5; DOXORUBICIN; FLICE INHIBITORY PROTEIN; PACLITAXEL; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARBOPLATIN; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CASPASES; CELL LINE, TUMOR; CHONDROCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOPOTECAN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3242659227     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.04.012     Document Type: Article

References (23)

1. Griffith T.S., Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10(5):1998 (Oct.);559-563
2. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev., Cancer. 2(6):2002 (Jun.);420-430
3. Abe K., Kurakin A., Mohseni-Maybodi M., Kay B., Khosravi-Far R. The complexity of TNF-related apoptosis-inducing ligand. Ann. N. Y. Acad. Sci. 926:2000;52-63
4. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature. 388(6638):1997 (Jul. 10);190-195
5. Chou T.C., Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 4:1983;450-454
6. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55
7. Sacks P.G., Harris D., Chou T.C. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int. J. Cancer. 61:1995;409-415
8. Grunt T.W. Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells. Cancer Lett. 189:2003;147-156
9. Tomek S., Koestler W., Horak P., Grunt T., Brodowicz T., Pribill I., et al. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur. J. Cancer. 39(9):2003;1318-1329
10. Kim K., Fisher M.J., Xu S.Q., el-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6(2):2000;335-346
11. Ozoren N., Fisher M.J., Kim K., Liu C.X., Genin A., Shifman Y., et al. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol. 16(5):2000 (May);917-925
12. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., Brognara C.B., Tschopp J., Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 60(16):2000 (Aug. 15);4315-4319
13. Poulaki V., Mitsiades N., Romero M.E., Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res. 61(12):2001 (Jun. 15);4864-4872
14. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161(6):1998 (Sep. 15);2833-2840
15. Leverkus M., Neumann M., Mengling T., Rauch C.T., Brocker E.B., Krammer P.H., et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 60(3):2000 (Feb. 1);553-559
16. Burns T.F., El-Deiry W.S. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276(41):2001 (Oct. 12);37879-37886
17. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89(2):1997 (Apr. 18);309-319
18. Cuello M., Ettenberg S.E., Nau M.N., Lipkowitz S. Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 81:2001;380-390
19. Vignati S., Codegoni A., Polato F., Broggini M. TRAIL activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur. J. Cancer. 38:2002;177-183
20. Siervo-Sassi R.R., Marrangoni A.M., Feng X., Naoumova N., Winans M., Edwards R.P., et al. Physiological and molecular effects of APO2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett. 190:2003;61-72
21. Juan S., Dexian Z., Kwan M., Sheung-tat F., Ruian X. TRAIL: a potential agent for cancer therapy. Curr. Molec. Med. 3:2003;727-736
22. Lancaster J.M., Sayer R., Blanchette C., Calingaert B., Whitaker R., Schildkraut J., et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin. Cancer Res. 9(2):2003 (Feb.);762-766
23. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104(2):1999 (Jul.);155-162